Reports Q4 revenue $30.61M, consensus $29.08M. Reports Q4 system-wide comp sales of 5%. “During 2023, our team delivered growth in system-wide sales, revenue, Adjusted EBITDA, the number of patient visits, and the number of patients treated as well as improved new patient conversion and existing patient attrition rates in a market of ongoing uncertainty among our patient demographic,” said Peter Holt, president and CEO of The Joint Corp. “Yet, we aim to do better and are implementing marketing initiatives to drive top-line growth through increased new patient count and patient engagement. Simultaneously, we are refranchising the majority of our corporate clinics, which we expect to ultimately increase our bottom line and cash flow. These actions will create opportunities for us to reinvest in The Joint and strengthen the health of our franchise network. As we advance our vision to be the Champions of Chiropractic, we expect to generate value for all of our stakeholders.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on JYNT:
- The Joint Corp. Reports Fourth Quarter and Year-end 2023 Financial Results
- JYNT Upcoming Earnings Report: What to Expect?
- The Joint Corp. to Participate in the 36th Annual Roth Conference
- The Joint Corp. to Host Conference Call on Thursday, March 7th to Discuss Fourth Quarter and Year-end 2023 Results
- The Joint Corp. Reports 2023 Operating Metrics